Development of a high-performance liquid chromatographic method for the determination of a new potent radioiodinated melanoma imaging and therapeutic agent

被引：11

作者：

Denoyer, Delphine ^{[1
]}

Labarre, Pierre ^{[1
]}

Papon, Janine ^{[1
]}

Miot-Noirault, Elisabeth ^{[1
]}

Galmier, Marie-Josephe ^{[1
]}

Madelmont, Jean-Claude ^{[1
]}

Chezal, Jean-Michel ^{[1
]}

Moins, Nicole ^{[1
]}

机构：

[1] Univ Auvergne, Ctr Jean Perrin, INSERM, EA 4231, F-63005 Clermont Ferrand, France

来源：

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2008年 / 875卷 / 02期

关键词：

Radiopharmaceutical targeting melanoma; N-(2-diethylaminoethyl)-6-iodoquinoxaline-2-carboxamide; ICF; 01012; HPLC analysis;

D O I：

10.1016/j.jchromb.2008.09.021

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

N-(2-diethylaminoethyl)-6-iodoquinoxaline-2-carbamide(ICF 01012) is a new melanoma imaging agent showing promising properties for application in internal radionuclide therapy. We developed an analytical protocol for detection of ICF 01012 in biological samples using HPLC. The proposed method was first validated using standard of ICF 01012 and four potent metabolites of this compound and then applied to follow the metabolic fate of [(125)I]ICF 01012 after injection in melanoma-bearing mice. The results demonstrate that this method exhibits a good linearity (r(2) = 0.9947), specificity and acceptable accuracy. This simple method appears convenient and sufficient for pharmacokinetic studies on [(125)I]ICF 01012. (c) 2008 Elsevier B.V. All rights reserved.

引用

页码：411 / 418

页数：8

共 20 条

[1] [Anonymous], 2005, INT C HARM ICH TECHN
[2] Clinical study of [123I] N-(2-diethylaminoethyl)-4-iodobenzamide in the diagnosis of primary and metastatic ocular melanoma
Bacin, F
Michelot, J
Bonafous, J
Veyre, A
Moreau, MF
Kemeny, JL
Chossat, F
Bekhechi, D
[J]. ACTA OPHTHALMOLOGICA SCANDINAVICA, 1998, 76 (01): : 56 - 61
[3] Chéhadé F, 2005, J NUCL MED, V46, P1701
[4] Chehade F, 2001, CELL MOL BIOL, V47, P529
[5] Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma
Chezal, Jean-Michel
Papon, Janine
Labarre, Pierre
Lartigue, Claire
Galmier, Marie-Josephe
Decombat, Caroline
Chavignon, Olivier
Maublant, Jean
Teulade, Jean-Claude
Madelmont, Jean-Claude
Moins, Nicole
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (11) : 3133 - 3144
[6] In vitro studies on the cellular uptake of melanoma imaging aminoalkyl-iodobenzamide derivatives (ABA)
Dittmann, H
Coenen, HH
Zölzer, F
Dutschka, K
Brandau, W
Streffer, C
[J]. NUCLEAR MEDICINE AND BIOLOGY, 1999, 26 (01) : 51 - 56
[7] Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake:: Structure-affinity relationships, metabolic fate, and intracellular localization
Eisenhut, M
Hull, WE
Mohammed, A
Mier, W
Lay, D
Just, W
Gorgas, K
Lehmann, WD
Haberkorn, U
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (21) : 3913 - 3922
[8] Diagnosis and treatment of cutaneous melanoma: state of the art 2006
Garbe, Claus
Elgentler, Thomas K.
[J]. MELANOMA RESEARCH, 2007, 17 (02) : 117 - 127
[9] Ultra-structural cell distribution of the melanoma marker iodobenzamide: improved potentiality of SIMS imaging in life sciences
Guerquin-Kern, Jean-Luc
Hillion, Francois
Madelmont, Jean-Claude
Labarre, Pierre
Papon, Janine
Croisy, Alain
[J]. BIOMEDICAL ENGINEERING ONLINE, 2004, 3 (1)
[10] Melanin affinity of N-(2-diethylaminoethyl)-4-lodobenzamide, an effective melanoma imaging agent
Labarre, P
Papon, J
Moreau, MF
Moins, N
Bayle, M
Veyre, A
Madelmont, JC
[J]. MELANOMA RESEARCH, 2002, 12 (02) : 115 - 121

← 1 2 →